New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2014
09:14 EDTC, BAX, LULU, GME, WGO, YONG, ADXSOn The Fly: Pre-market Movers
HIGHER: Baxter (BAX), up 9% after announcing plans to split into two separate companies... Winnebago (WGO), up 7% after quarterly results top expectations... lululemon (LULU), up 1% after quarterly earnings beat expectations, but full-year EPS view trails consensus estimate. LOWER: Citigroup (C), down 5.6% after the Federal Reserve rejected the bank's capital plan for 2014, shares were downgraded at Keefe Bruyette and Bernstein... GameStop (GME), down 4.6% after earnings and guidance miss expectations... Advaxis (ADXS), down 27% after 4.08M share spot secondary offering priced at $3.00.
News For C;BAX;LULU;GME;WGO;YONG;ADXS From The Last 14 Days
Check below for free stories on C;BAX;LULU;GME;WGO;YONG;ADXS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
August 22, 2014
05:33 EDTGMEGameStop FY14 outlook may prove conservative, says Piper Jaffray
Piper Jaffray believes GameStop's outlook for FY14 may prove conservative as second half same-store-sales estimates look low. Piper views GameStop's Q2 results as solid and raised its price target for shares to $53 from $52 while keeping an Overweight rating on the stock.
August 21, 2014
18:22 EDTGMEOn The Fly: After Hours Movers
Subscribe for More Information
16:09 EDTGMEGameStop up 10.6% after reporting Q2 results, guidance for Q3, FY14
Subscribe for More Information
16:08 EDTGMEGameStop sees FY14 EPS $3.40-$3.70, consensus $3.68
Subscribe for More Information
16:07 EDTGMEGameStop sees Q3 EPS 58c-64c, consensus 59c
Sees Q3 SSS up 1%-5%.
16:02 EDTGMEGameStop reports Q2 EPS 22c, consensus 18c
Subscribe for More Information
15:37 EDTBAXNektar: Baxter announces positive results from Phase 3 study of BAX 855
Nektar Therapeutics (NKTR) reports Baxter International (BAX) announced positive results from its Phase 3 pivotal clinical trial of BAX 855, an investigational, extended half-life recombinant factor VIII treatment for hemophilia A based on ADVATE, which met its primary endpoint in reducing annualized bleed rates in the prophylaxis arm compared to the on-demand arm. Top-line results from the prospective, global, multi-center Phase 3 study demonstrated that BAX 855 met its primary endpoint in the control and prevention of bleeding, routine prophylaxis and perioperative management for patients who were 12 years or older. Patients in a twice-weekly prophylaxis arm experienced a 95 percent reduction in median ABR as compared to those in the on-demand arm (1.9 vs. 41.5, respectively). BAX 855 was also effective in treating bleeding episodes, 96 percent of which were controlled with one or two infusions. The half-life of BAX 855 was 1.4 - 1.5 times that of ADVATE, consistent with the findings from the Phase 1 study. No patients developed inhibitors to BAX 855 and no treatment-related serious adverse events, including hypersensitivity, were reported. The most common product-related adverse event was headache. Baxter expects to submit a Biologics License Application for BAX 855 to the U.S. Food and Drug Administration before the end of 2014 and will present additional data in the coming months. In addition to an ongoing continuation study for patients who have completed the pivotal trial, the company is initiating a Phase 3, prospective, open-label, multi-center study to evaluate the safety and efficacy of BAX 855 among 60 previously treated patients under the age of 12 with severe hemophilia A. Consistent with guidelines published by the European Medicines Agency that require a study in children less than 12 years of age prior to filing, Baxter expects to file a Marketing Authorization Application with the EMA upon the completion of the pediatric study
15:15 EDTGMENotable companies reporting after market close
Subscribe for More Information
14:52 EDTGMEGameStop technical comments ahead of results
Subscribe for More Information
10:02 EDTCActive calls at CBOE; AAPL C HPQ
Active calls at CBOE; AAPL 8/22/14 100 & 100, C Jan 55, HPQ 8/29/14 36
09:57 EDTGMEGameStop August weekly 41 straddle priced for 6.7% move into Q2
09:02 EDTBAXBaxter announces BAX 855 met primary endpoint in Phase 3 study
Baxter announced "positive" results from its Phase 3 pivotal clinical trial of BAX 855, which met its primary endpoint in reducing annualized bleed rates in the prophylaxis arm compared to the on-demand arm. Top-line results from the prospective, global, multi-center Phase 3 study demonstrated that BAX 855 met its primary endpoint in the control and prevention of bleeding, routine prophylaxis and perioperative management for patients who were 12 years or older. Patients in a twice-weekly prophylaxis arm experienced a 95% reduction in median ABR as compared to those in the on-demand arm. BAX 855 was also effective in treating bleeding episodes, 96% of which were controlled with one or two infusions. The half-life of BAX 855 was 1.4 – 1.5 times that of ADVATE, consistent with the findings from the Phase 1 study. No patients developed inhibitors to BAX 855 and no treatment-related serious adverse events, including hypersensitivity, were reported. The most common product-related adverse event was headache. Baxter expects to submit a Biologics License Application for BAX 855 to the U.S. Food and Drug Administration before the end of 2014 and will present additional data in the coming months. In addition to an ongoing continuation study for patients who have completed the pivotal trial, the company is initiating a Phase 3, prospective, open-label, multi-center study to evaluate the safety and efficacy of BAX 855 among 60 previously treated patients under the age of 12 with severe hemophilia A. Consistent with guidelines published by the European Medicines Agency that require a study in children less than 12 years of age prior to filing, Baxter expects to file a Marketing Authorization Application with the EMA upon the completion of the pediatric study.
06:43 EDTCRegulators up bank warning efforts for poor risk assessment, Reuters says
Subscribe for More Information
06:26 EDTGMEGameStop August weekly volatility elevated into Q2 and revenue outlook
GameStop August weekly call option implied volatility is at 163, September is at 47, January is at 40; compared to it 26-week average of 43 according to Track Data, suggesting large near term price movement into the expected release of Q2 today.
August 20, 2014
06:17 EDTCCitigroup looks to sell Japanese retail banking unit, Reuters says
Subscribe for More Information
August 19, 2014
16:33 EDTBAXBaxter to expand Alabama facility to increase dialyzers production
Subscribe for More Information
13:08 EDTCCitigroup tells appeals court Agentina banking license at risk, Reuters reports
Subscribe for More Information
12:14 EDTCCitigroup considers selling Japan retail-banking unit, WSJ reports
Subscribe for More Information
09:28 EDTGMEGameStop says CEO underwent unexpected surgery for tumor
GameStop disclosed in a regulatory filing that late last week Paul Raines, its CEO, underwent unexpected surgery during which a "very small, cancerous tumor was identified and successfully removed from an easily accessible part of the brain." The company added, "Because it was found very early, his doctors have advised him that his prognosis for a full and complete recovery is very good. The next step is for Paul to undergo preventive chemotherapy. Recovery from this process is expected to take about six weeks. This regimen will restrict his travel during that period, but will not interfere with his continued leadership of the Company." Daniel DeMatteo, Executive Chairman, said, "Speaking for the Board, we have every confidence in Paul’s continued leadership and wish him a speedy recovery. While he recovers, our highly-tenured executive team will ensure that our business continues without interruption."
06:11 EDTGMEGameStop FY14 guidance likely in-line, says Piper Jaffray
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use